Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
dstock07734,
It was on a slide on October 26, 2022.
That was at the end of 2014. And then came the summer of 2015.....
dstock07734,
anti-PD1= Pembrolizumab 400 mg q 6 weeks.
Rh2022,
Linda Powers’ Speech Transcript at the Oppenheimer 25th Annual Health Conference on 12-10-14.
sentiment,
I agree.
.
Feb.2020. Shenell is now living 51 glorious months after being diagnosed with GBM.
https://www.instagram.com/p/Coa2fESK0qB/
https://www.facebook.com/photo.php?fbid=10221078017250630&set=pcb.10221078018690666&type=3&theater
jm100,
Today, Dr. David W. Andrews, an Imvax co-founder and Chief Medical Officer spoke about " a Phase 2b Study of IGV -001 in Newly Diagnosed Glioblastoma" here;
Plus Therapeutics to present at EBCI's virtual educational event this Friday at 12 pm PT / 3 pm ET.
— Plus Therapeutics (Nasdaq: PSTV) (@plustxinc) May 15, 2023
Register now: https://t.co/Jq67TondMV#btsm #NIH #clinicaltrial #gbm #glioblastoma #neurosurgery #nuclearmedicine #oncology #raredisease #targeted #radiation #therapy https://t.co/IncldMqkdO pic.twitter.com/0PsWbIUXQp
ATLnsider,
I ask Leia Nghiemphu,
Confirmation that current combo Clinical Trial of DC vaccine + poly-ICLC + PD-1 mAb is in Pase 2. (Window of Opportunity Trial)
Min.54
2023 UCLA Brain Tumor Conference : Updates in Experimental Therapies by Leia Nghiemphu MD
Professor of Clinical Neurology
UCLA Medical Center (Ronald Reagan)
http://events.provideriq.com/Event.aspx?i=840&y=cc0ad4ce-a347-4734-976c-40ad753ada03
Thanks for the full text, dstock7734!
Thank you for sharing pgsd! Much, much appreciated!
Thanks pgsd.
I'm curious but how did you get the full text of the reply?
Thanks pgsd!
Do you have access to this :https://jamanetwork.com/journals/jamaoncology/article-abstract/2805079?resultClick=1
Comment & Response
May 18, 2023
External Control Arms and Data Analysis Methods in Nonrandomized Trial of Patients With Glioblastoma
Jacob J. Mandel, MD1; John F. de Groot, MD2
Author Affiliations
1Department of Neurology and Neurosurgery, Baylor College of Medicine, Houston, Texas
2The University of California, San Francisco
JAMA Oncol. Published online May 18, 2023. doi:10.1001/jamaoncol.2023.1066
Comment & Response
May 18, 2023
External Control Arms and Data Analysis Methods in Nonrandomized Trial of Patients With Glioblastoma—Reply
Linda M. Liau, MD, PhD; Keyoumars Ashkan, MD; Marnix L. Bosch, PhD
JAMA Oncol. Published online May 18, 2023. doi:10.1001/jamaoncol.2023.1072
Agreed.
I said:
Northwest Biotherapeutics is listed as a sponsor here. Unfortunately no presentation.
Plus Therapeutics to present at EBCI's virtual educational event this Friday at 12 pm PT / 3 pm ET.
— Plus Therapeutics (Nasdaq: PSTV) (@plustxinc) May 15, 2023
Register now: https://t.co/Jq67TondMV#btsm #NIH #clinicaltrial #gbm #glioblastoma #neurosurgery #nuclearmedicine #oncology #raredisease #targeted #radiation #therapy https://t.co/IncldMqkdO pic.twitter.com/0PsWbIUXQp
ATLnsider,
Poly-ICLC is used along with DCVax-L in this combo trial since last summer 2022, IMO. (Evidence: Linda Liau's presentation on Oct.26, 2022)
The first 20-23 patients enrolled between Jan.2020 - May 2022 did not receive Poly-iclc, IMO.
Min.32.40s
I wrote::
Lots of media attention today for the results of a Phase 1/2 clinical trial investigating the safety and effectiveness of a novel therapy that combines the injection of an oncolytic virus – a virus that targets and kills cancer cells – directly into the tumor, with intravenous immunotherapy. (Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial)
The results, published in Nature Medicine, show that this combination therapy is safe, well tolerated and prolongs patient survival. The therapy had no major unexpected adverse effects and yielded a median survival of 12.5 months—considerably longer than the six to eight months typically seen with existing therapies.
The patients in the trial did not have tumor resection at recurrence – only injection of the virus through a small hole and a purpose-built catheter. Then, patients received an anti-PD-1 antibody intravenously, every three weeks, starting one week after surgery.
A new paper published in @NatureMedicine by Drs. @gelarehzadeh and @FarshadNassiri @UHN @uoftmedicine using a novel combination approach to #glioblastoma treatment shows promise, extending survival.
— Krembil Brain Institute (@KBI_UHN) May 15, 2023
Learn more: https://t.co/PnmbUzfD8C#BrainTumorAwarenessMonth #Braintumor pic.twitter.com/fxkXgE2BK4
Flipper44,
I think LL uses poly-iclc to get those results.
Wednesday, October 26, 2022
“The Promise of Immunotherapy for Treatment of Glioblastoma”
Linda Liau:
Thanks for sharing ATLnsider. Good info!
hope4patients,
I'm so sorry. It is heartbreaking and incredibly cruel.
I’ve followed Laura’s journey with hope and admiration. Laura, Nicola, Mark and Gracie are all amazing.
Sending love and strength to Laura and all of the family.
"Hope is the hardest thing to kill."
— OurBrainBank (@ourbrainbank) May 4, 2023
Heartbreaking words from an incredible mum about her amazing daughter. Thinking about Laura and her family every day.
The world must do better. #GBM #Glioblastoma #BTSM #GoGrayInMay #BrainTumorAwarenessMonth #BrainCancer https://t.co/xDjNzJSNk3
I agree.
October 27, 2022
Flipper44,
Four years ago, May 28, 2019, the patient had her first craniotomy to remove a large brain tumor in her right frontal lobe.
After surgery the tumor was confirmed as a Grade IV Glioblastoma.
Shortly thereafter she had a surprise second craniotomy for an infection, complete with severe pain from post herpetic neuralgia, a blood clot, lymphedema, not to mention six weeks of daily radiation and chemotherapy.
On May 21, 2021 she was officially enrolled in the clinical trial. https://clinicaltrials.gov/ct2/show/NCT04201873?cond=atl-dc&draw=2&rank=1
She had her first infusion of the “immunotherapy drug” (Pembrolizumab or Placebo) 14 days before her surgery on June 7, 2021.
About a month after surgery she received three doses of the vaccine DCVax-L across 6 weeks.
On May 28, 2021 she wrote:
flipper44,
My guess is the data was collected around August-September 2022.
One of the patients in the combo trial underwent her third craniotomy on June 7, 2021 at UCLA Medical Center in Los Angeles, CA and is still alive.
She is one of the 4 censors between 420 and 480 days, IMO. (2 on the blue line and 2 on the red line)
Linda Liau's lecture "The Promise of Immunotherapy for Treatment of Glioblastoma" on Wednesday, October 26, 2022
Stuart Rowe lecture at the University of Pittsburgh.
That's correct Doc logic.
Preconditioning the immune system with a tetanus/diphtheria toxoid significantly improved the effectiveness of dendritic cell immunotherapy and extended overall survival in a small, randomized study of patients with glioblastoma.
Laura Nuttall is having intra tumoural viral therapy. One of the few available options left after GBM recurrence.
In Laura's case it's Newcastle disease but some clinics use polio or even the herpes virus .
She has had 2 ommaya reservoir implanted in her head which will allow the virus to be injected directly into the tumour site.
GBM is such a devastating disease.
I am so sorry to read this latest update.
Sending lots of love and strength to Laura and her family.
That's funny.
Seeking Alpha have an article on NWBO by Avisol Capital Partners on Dec.19,2021 and one day later there was the MIA/IMP License.
dennisdave,
From India. Wonder why they are invested.
Avisol Capital Partners - Northwest Biotherapeutics: No TLD Yet. Dec.19, 2021.
ATLnsider,
Toll-like receptor (TLR) agonists (e.g., imiquimod, poly-ICLC) has been tested in a Phase I/II clinical trial (NCT00068510 , July 2003- October 2007)
These immune response modifiers were used only in the booster phase of the protocol, after patients had shown acceptable toxicity profiles to DC-lysate vaccinations alone.
Prins et al., 2011
https://aacrjournals.org/clincancerres/article/17/6/1603/12140/Gene-Expression-Profile-Correlates-with-T-Cell
Thanks for sharing StonkMaster.